Full-Service CDMO Partner: From Innovative Formulation to Global Delivery
| Stage | Service Scope | Estimated Timeline |
|---|---|---|
| Phase 1: R&D & Custom Formulation | In-depth analysis of ingredients (e.g., NAD+, Magnesium Glycinate, Omega-3) to optimize stability and bioavailability. | 1-3 days |
| Phase 2: Pilot Trials & Feasibility | Small-batch trial runs and accelerated stability testing to ensure formula integrity. | 2 - 3 Weeks |
| Phase 3: Material Sourcing & Pre-treatment | Strict raw material verification and professional pre-mixing under controlled environments. | 3-5 days |
| Phase 4: Scale-up Manufacturing | High-speed filling and patented 360° Banding/Sealing for zero-leakage assurance. | 2 - 3 Weeks |
| Phase 5: Quality Control & Lab Analysis | 7-stage rigorous testing, including assay, microbial, and disintegration tests. | 1 Week |
Note: The timelines provided above are standard estimates. Actual service duration may vary depending on the complexity of each client's specific formulation and will be communicated by your dedicated Product Manager during the service process.
![]()
World-Class Hardware: 16 fully automated innovative production lines ensuring a total capacity of 1.2 million capsules/day.
![]()
Precision Dosing: Advanced sensors maintain Content Uniformity >99%, ideal for high-potency and low-dosage formulas.
Purity & Safety: Non-EO (Ethylene Oxide) Sterilization process. We guarantee zero chemical residue, offering the cleanest profile for sensitive ingredients.
![]()
Global Compliance: TiO2-Free and SLS-Free solutions. Certified by cGMP, HALAL, KOSHER, ISO 9001/22000. We provide full documentation for US DMF and EU registration.
Liquid-Filled Hard Capsules (LFHC): Boost bioavailability by up to 300% for lipid-based nutrients.
Capsule-in-Capsule Technology: Physical isolation for incompatible ingredients with sequential release.
Beadlets-in-Capsule Filling: Targeted intestinal release for active ingredients like prebiotics using enteric coating.
Specialized Coatings: Enteric-coated and Delayed-release (DR) solutions for targeted intestinal delivery of probiotics and enzymes.
![]()
Infrastructure: 100,000 m² state-of-the-art production base.
R&D Center: Advanced laboratories in Wuhan and Chibi.
Market Reach: Successfully serving clients in the USA, EU, Japan, and Southeast Asia.
![]()